• Abeona Therapeutics published its Third Quarter 2026 Financial Results and Corporate Update presentation, including clinical data for EoE candidate ABO-801.
• Pooled Phase 3 data showed complete response rates of 18% for ABO-801 versus 6% for placebo at week 12.
• Net ZEVASKYN revenue rose 18% quarter over quarter to $13.5 million.
• The ABO-801 acquisition involved $20 million in equity issued to the seller, with no upfront cash consideration.
• A $30 million private placement supplements September 30 liquidity of $134.9 million, which excludes the placement proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.